) recently received approval in the US for the initiation of a
multi-center, open-label phase IIa study on BL-8040. BioLineRx is
looking to develop BL-8040 for the treatment of acute myeloid
leukemia (AML) and other types of hematological cancers.
The study will evaluate the safety and efficacy of repeated
escalating doses of BL-8040 in adults suffering from
relapsed/refractory AML. Secondary endpoints include
pharmacokinetic profile of the candidate and an efficacy
BioLineRx expects partial results in the fourth quarter of
2013, while the final results are expected in the second half of
We remind investors that in Sep 2012, the rights to BL-8040
were in-licensed by the company from Biokine Therapeutics
As per BioLineRx, approximately 250,000 adults worldwide are
diagnosed with AML every year. In spite of efforts being made to
develop therapies for AML, less than 25% of patients survive 5
years after being diagnosed with the disease.
Currently available treatments include chemotherapy, radiation
therapy and stem cell transplantation.
Eisai Co., Ltd.
Johnson & Johnson
) are together trying to develop Dacogen (decitabine) for
BioLineRx, a biopharmaceutical company, carries a Zacks Rank
#3 (Hold). We remind investors that the company suffered a
pipeline setback recently with disappointing interim results
being reported from the phase II/III CLARITY trial of BL-1020,
being developed for the treatment of schizophrenia. The interim
analysis indicated that the study will not meet its primary
) look well-positioned in the biopharma space. UCB carries a
Zacks Rank #1 (Strong Buy).
BIOLINE RX LTD (BLRX): Get Free Report
EISAI CO LTD (ESALY): Get Free Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis
UCB SA (UCBJF): Get Free Report
To read this article on Zacks.com click here.